Skip to main content

Table 1 DOTs per 1000 patient-days of oral antibiotics in the Department of Oral and Maxillofacial Surgery

From: Effect of educational intervention on the appropriate use of oral antimicrobials in oral and maxillofacial surgery: a retrospective secondary data analysis

 

Outpatients

Inpatients

2013

2018

2013

2018

First- and second-generation cephalosporinsa

0 (0, 0)

0 (0, 0)

0 (0, 0)

0 (0, 0)

Third-generation cephalosporinsb

218 (197, 233)

2.5 (1.4, 3.3)i

170 (142, 199)

0 (0, 0)i

Macrolides

169 (158, 179)

70.8 (60.2, 81.4)i

59.4 (47.6, 73.8)

28.3 (11.6, 32.9)i

Short-actingc

0 (0, 0)

 

0 (0, 0)

0 (0, 49.4)j

Medium-actingd

138 (125, 162)

0 (0, 0)

41.9(19.2, 49.6)

0 (0, 5.0)i

Long-actingee

27.2 (19.5, 37.0)

52.9 (41.0, 68.7)i

18.8 (17.6, 25.6)

10.5 (5.5, 19.1)i

Quinolones

57.0 (41.7, 80.9)

15.9 (14.0, 19.4)i

21.4 (13.3, 32.5)

24.5 (14.6, 32.9)

Second-generationf

9.4 (8.1, 16.9)

35.6 (28.6, 40.8)i

16.6 (7.9, 32.5)

0 (0, 1.9)i

Third-generationg

47.7 (34.1, 68.8)

7.3 (4.4, 10.2)

0 (0, 0)

19.5 (14.6, 28.2)j

Penicillins

25.3 (18.9, 32.3)

24.9 (23.5, 32.5)i

7.1 (6.0, 12.7)

115 (79.8, 118)j

Amoxicillin

25.3 (18.9, 32.3)

185 (170, 195)j

7.1 (6.0, 12.7)

103 (74.7, 116)

Clavulanate/amoxicillin

0 (0, 0)

181 (168, 195)

0 (0, 0)

0 (0, 12.7)

Clindamycin

0 (0, 1.5)

0.8 (0, 7.0)

0 (0, 0)

13.4 (10.5, 19.4)j

Tetracyclinesh

0 (0, 0)

2.5 (0. 5.1)

0 (0, 1.1)

0 (0, 4.6)

Metronidazole

0 (0, 0)

0 (0, 2.0)j

0 (0, 0)

12.6 (0, 18.9)j

Fosfomycin

0 (0, 0)

5.1 (0, 13.9)j

0 (0, 0)

0 (0, 0)

Others

 

0 (0, 0)

  

Sulfamethoxazole/

0 (0, 0)

 

0 (0, 0)

0 (0, 5.1)

Trimethoprim

 

0 (0, 0)

  

Total

464 (451, 502)

310 (282, 345)i

278 (227, 319)

211 (176, 250)i

  1. Median (first quartile, third quartile)
  2. DOTs days of therapy
  3. aCefalexin, cefaclor
  4. bCefcapene pivoxil, cefditoren–pivoxil, cefteram–pivoxil, cefdinir
  5. cErythromycin
  6. dClarithromycin, roxithromycin
  7. eAzithromycin
  8. fLevofloxacin, ciprofloxacin, tosufloxacin, ofloxacin
  9. gSitafloxacin, garenoxacine, moxifloxacin, prulifloxacin
  10. hMinocycline, doxycycline
  11. iDOTs in 2018 decreased significantly compared to those in 2013
  12. jDOTs in 2018 increased significantly compared to those in 2013